se gb


Bo Jesper Hansen

Chairman and Board member since 2013. Born 1958. MD. PhD. Other appointments Chairman of Swedish Orphan Biovitrum AB. Board member of GenSpera Inc., Newron SA, Ablynx NV, Orphazyme A/S and CMC Kontrast AB. Previous appointments include various positions in Swedish Orphan International AB since 1993, including CEO 1998–2010. Medical advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi. Founder of Scandinavian Medical Research. Holdings in Karolinska Development SEK 400,000 convertible loan.


Bo Jesper Hansen.png

Tse Ping

Vice Chairman and Board member since 2015. Born 1952. Honorary Doctorate, Fil Dr hc. Other appointments Founder and Chairman of Sino Biopharmaceutical Limited, Vice Chairman of Charoen Pokphand Group (CP Group), where he has extensive experience of major merger and acquisition activity including Ping An Insurance, CITIC Group, China Mobile, ITOCHU Corporation, and Marko Group. Previous appointments include Member of the Ninth, Tenth, and Eleventh National Committee of the Chinese People’s Political Consultative Conference. Holdings in Karolinska Development 4,853,141 shares and SEK 272,858,294 in convertible bonds (by related legal person).



Niclas Adler

Board member since 2015. Born 1971. PhD, MSc. Other appointments Managing Partner Accelerated Innovation Ltd, President Indonesian International Institute for Life-sciences, Chairman PT Accelerated Value, Chairman e-Cognition PTE Ltd, Chairman ITH Immune Therapy Holdings AB, Chairman TLA Targeted Immunotherapies AB, Chairman Accelerated Drug Development AB and Babson Global Professor of Entrepreneurship Practice. Previous appointments include President IPMI International Business School, Jakarta, Director Truepoint Partners, Boston, Fellow, Sunningdale Institute, London, Fellow, Centre For International Business and Management, Judge Business School, Cambridge University, CEO Jönköping International Business School, Director FENIX Center for Innovations in Management, Stockholm School of Economics, Executive Director, Stockholm School of Entrepreneurship. No holdings in Karolinska Development.




Vlad Artamonov

Board member since 2012. Born 1978. MBA, B.Sc. Other appointments Board Member of Redbank Energy Ltd. and of Coastal Capital International Ltd., Managing Partner at Coastal Capital International Ltd. Previous appointments include Investment Analyst at Greenlight Capital Inc., position in the Global Merger & Acquisition Group at Merrill Lynch in New York. Holdings in Karolinska Development 3,470,541 shares (by related legal person).


Khalid Islam

Board member since 2015. Born 1955. PhD. Other appointments Chairman of Fennec Pharma Inc. and Minoryx Therapeutics SL.; Board member of Oxthera AB and Molmed SpA.; Advisor to Kurma Biofund, member of the Editorial Board of Current Drug Discovery & Technologies. Previous appointments include President and CEO of Gentium SpA and Arpida AG and various leadership positions in research and development in Hoechst Marion Roussel (HMR) and Marion Merrell Dow (MMD).. No holdings in Karolinska Development.



Henrijette Richter

Board member since 2014. Born 1971. PhD MSc. Other appointments Partner at Sofinnova Partners, Paris and board member of Asceneuron SA.. Previous positions include Investment Director at Novo Seeds, Novo A/S (2007-2014) where she served on the boards of Cytoguide ApS, Avilex Pharma ApS, Affinicon ApS, Orphazyme A/S and EpiTherapeutics A/S. In addition she is on the Board of Directors for the Green Development and Demonstration Programme (GUDP) of the Danish Food, Agriculture and Fisheries Ministry. No holdings in Karolinska Development.


Henrijette Richter.png

Carl Johan Sundberg

Board member since 2014. Born 1958. Professor of Physiology. Other appointments Board Director of Cobra Biologics AB, Board Director of Saniona AB, member of Karolinska Institutet Innovation Council, research director of the Unit of Bioentrepreneurship, Fellow of the Royal Swedish Academy of Engineering Sciences, member of the Medical Commission of the International Olympic Committee, Inspector General of the Medical Association and Chairman of Research!Sweden. Previous assignments include Investment Director at Karolinska Investment Fund, Board Director of Global Genomics AB, AngioGenetics AB, NsGene AS, Cellectricon AB, Alfta Rehab Center Holding AB, Karolinska Education AB and Feelgood Swedish AB, Vice President of Euroscience and Chairman of the Swedish Professional Associations for Physical Activity and Sports Medicine. No holdings in Karolinska Development.


CJ Sundberg.png

Hans Wigzell

Board member since 2006. Born 1938. Professor Emeritus of Immunology and MD. Other appointments Chairman of Rhenman & Partner Asset Management AB. Board member of  Swedish Orphan Biovitrum AB, Valneva SA, Sarepta Therapeutics Inc.  and RaySearch Laboratories AB. Member of The Royal Swedish Academy of Engineering Sciences and of the Royal Swedish Achademy of Sciences. Previous assignments include, among others, the President of Karolinska Institutet's Nobel Committee, and President of Karolinska Institutet and Director General of Smittskyddsinstitutet. Holdings in Karolinska Development 8,491 shares and SEK 39,992 convertible loan.

  Hans W_ram.png